Last reviewed · How we verify
NCT06921213: Cares-1
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
Phase 2 trial testing Linezolid (LZD) in Syphilis, Congenital in 90 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | London School of Hygiene and Tropical Medicine |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 October 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 3 locations across South Africa, Malawi, Indonesia |
Drugs / interventions tested
- Linezolid (LZD) — full drug profile →
- Amoxicillin (amoxicillin) — full drug profile →
- Benzathine Penicillin G — full drug profile →
Conditions studied
- Syphilis, Congenital — all drugs for Syphilis, Congenital →
Sponsor
London School of Hygiene and Tropical Medicine
Who can join
Adults 0 Days to 7 Days, any sex, with Syphilis, Congenital. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06921213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Linezolid (LZD)
Trials testing the same drug.
- NCT07301294 — Microbiological Characteristics of Biofilm on Double J Ureteral Stents After Lithotripsy. · Phase 4 · not yet recruiting
- NCT07198685 — 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province · NA · not yet recruiting
- NCT06761131 — Compare Linezolid-Induced Thrombocytopenia in Patients With Normal Renal Function Versus Impaired Renal Function · completed
- NCT06811025 — Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis · Phase 1, PHASE2 · enrolling by invitation
- NCT06811012 — Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis · Phase 1, PHASE2 · enrolling by invitation
Other London School of Hygiene and Tropical Medicine trials
Trials by the same sponsor.
- NCT06923592 — Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar · Phase 3 · recruiting
- NCT06833736 — A Health App Using Recipes and Education Components to Facilitate Sustainable and Healthier Diets. · NA · completed
- NCT06166498 — Parasite Clearance and Protection From Infection (PCPI) in Zambia · Phase 3 · completed
- NCT06173206 — Parasite Clearance and Protection From Infection (PCPI) in Cameroon · Phase 3 · completed
- NCT06578572 — Seasonal R21 Mass Vaccination for Malaria Elimination · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06921213 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by London School of Hygiene and Tropical Medicine
- Last refreshed: 4 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06921213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing